| Website | cellerix.com |
| Category | BioTech |
| Phone | +34 91 804 92 64 |
| Employees | |
| Founded | 2004 |
| Description | Stem Cell Therapy |
| Total | $64.9M |
| Series B, 9/07 Life Sciences Partners Ventech Ysios Capital Roche Venture Fund Novartis Venture Funds Biopartners Capital | €27.2M |
| Series C, 1/10 Ysios Capital Life Sciences Partners Ventech Grupo Genetrix Roche Venture Fund Novartis Venture Fund | $37.7M |
Cellerix, S.A., a biotechnology company, engages in the development and production of medicines based on the use of stem cells of adult origin. The company offers products for the treatment of gastroenterology, dermatology, and immune-based diseases. Its products include Cx401, which is used for the treatment of complex perianal fistulas; and Cx501, a cell therapy product to be applied in the treatment of Epidermolysis Bullosa. Cellerix, S.A. was founded in 2004 and is based in Tres Cantos, Spain.
